Prograf (tacrolimus)

DRUG3 trials

Sponsors

East Carolina University, Astellas Pharma Inc, Veloxis Pharmaceuticals

Conditions

Kidney TransplantationLiver TransplantationRenal Failure

Phase 3

Pharmacokinetics of Tacrolimus in Liver Transplantation Patients Treated With Prograf and Modified Release Tacrolimus

CompletedNCT00909571

Astellas Pharma IncLiver Transplantation

Start: 2009-04-30End: 2010-03-31Updated: 2010-04-16

Double-Blind,Double-Dummy,Efficacy/Safety,LCP-Tacro™ Vs Prograf®,Prevention Rejection,De Novo Adult Kidney Tx

CompletedNCT01187953

Veloxis PharmaceuticalsRenal Failure

Start: 2010-09-30End: 2014-03-31Updated: 2016-05-18

Phase 4

Optima: Optimizing Prograf Therapy in Maintenance Allografts II

CompletedNCT00905515

East Carolina UniversityKidney Transplantation

Start: 2003-08-31End: 2008-07-31Updated: 2023-09-07

Related Papers

Effect of Concentration/Dose Ratio in De Novo Kidney Transplant Recipients Receiving LCP-Tacrolimus or Immediate-Release Tacrolimus: Post Hoc Analysis of a Phase 3 Clinical Trial

Annals of Transplantation2020-07-2810 citations